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Abstract
With the advent of highly conformal and adaptive radiotherapy techniques, the sig-
nificance of accurate delineation of organs at risk (OARs) is becoming more and more 
important. Techniques such as Intensity modulated radiotherapy (IMRT) and intensity/
volumetric modulated arc therapy (VMAT) has allowed for improved dose conformation 
within the target. It has also allowed for steep dose gradients around the target for better 
normal tissue sparing. The accurate contouring and delineation of the OARs are thus 
warranted as variation in delineation has been systematically reported in studies. All 
these facts have led to the development of contouring guidelines for OARs in various 
sites. Head and neck cancers (HNC) are a perfect example where outcome and quality 
of life (QOL) balance remains a therapeutic challenge. There are several OARs and thus 
the accurate delineation following a standard guideline becomes more important. This 
chapter looks into the published guidelines for the delineation of such structures.
Keywords: head and neck cancer, IMRT, VMAT, QOL, organs at risk
1. Introduction
The variation in the contouring and delineation of the different OAR’s has been systemati-
cally reported in studies [1]. We will be discussing the standard available guidelines and a 
simple practical way to delineate OAR’s in modulated radiotherapy for HNC. The OAR’s 
have been divided into five subgroups viz. optic structures, salivation related structures, 
structures related to swallowing, brachial plexus and intra-cranial structures.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Optic structures
2.1. Eye ball
The entire eye ball is to be contoured as a single structure. The entire retina is to be included.
For contouring of substructures of the eye the European particle therapy network (EPTN) has 
put forward a consensus based atlas based on CT and MRI [2].
2.1.1. Cornea
The cornea is located anterior to the vitreous humor, iris, lens and ciliary body [2]. It can be 
delineated in MRI or CT and is contoured with a 2-3 mm brush.
RT can injure the cornea by damaging the deeper layers of stroma, but in most cases the acute 
toxicity is as a result of loss of tear film [3].
Dose recommendation: < 40 Gy. Edema of the corneal stoma appears at a dose of 40-50Gy, but is 
usually transient. With doses of 60 Gy the chance of corneal ulceration is increased to 17–20% 
which increases further if chemotherapy is added.
2.1.2. Retina
It is the innermost layer of the globe and is about 0.25 mm in thickness and is not usually visu-
alized in a standard MRI [2]. Contoured using a 3 mm brush, the retina covers the posterior 
5/6th of the globe. The optic nerve is not contoured along with it [4].
Dose recommendations: Dmax—45Gy. Acute retinal toxicity is not reported. Being a part of the 
central nervous system, the retina behaves as a late reacting tissue [3]. Usually there is a latent 
period of 6 months to 3 years before the onset of clinically significant retinopathy. The mean 
latent period is 19 months [5].
2.1.3. Lens
Biconvex structure in the aqueous humor, it is clearly visible in CT [2]. The structure is about 
10 mm in diameter seen in the coronal plane.
Dose recommendations: Dmax—5 to 10 Gy. Acute lens toxicity is not reported. A single dose 
of 2 Gy can cause cataract, but is usually visually insignificant. [3] The time of onset is dose 
related. For doses in the range of 2.5–6.5Gy, the latency is 8 yrs. with the possibility of 33% 
progressive cataract, whereas doses of 6.5–11.5Gy, the latency reduces to 4 years with the 66% 
risk of progressive cataract.
2.2. Optic nerve
While moving craniocaudally, optic nerve is seen below the superior rectus. The nerve is 2-5 mm 
thick and is delineated from the posterior margin of retina and continued along its course pos-
teriorly till it merges with the optic chiasm after passing through the superior orbital fissure.
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Dose recommendations: Dmax <54 Gy. The incidence of radiation induced optic neuropathy 
(RION) is unusual for doses less than 55 Gy. At 55–60 Gy the risk becomes 3–7% and for doses 
>60 Gy the risk is quite significant at 7–20% [6].
2.3. Optic chiasm
A small structure is usually confined to 2 or 3 slices in the superior-inferior direction. Better 
demarcated in MRI, the chiasm is situated about 1 cm superior to the pituitary gland. Laterally 
it is bounded by the carotid arteries. It is better visible in MRI with a high signal on T1. A good 
landmark to look for is the pituitary stalk. It lies just posterior to the chiasm and appears 
hyperintense even on plain CT [7]. On average it measures 8 x 14 mm (APxTrans) and is about 
2–5 mm thickness in the super-inferior dimension [7].
It should be kept in mind that, the chiasm should be contoured in continuity with the optic 
nerves.
Dose recommendations: D max <54 Gy [6].
2.4. Lacrimal gland
Freedman et al. [8] has given a step-by-step instruction to contour the lacrimal gland. The 
contour starts by identifying the mid portion of the gland and thereafter tracking it superiorly 
and inferiorly.
Superior extend corresponds to the super-lateral corner of orbit, just below the orbital rim. 
Inferiorly it does not extend below the level of insertion of lateral rectus.
The gland is better delineated in brain (120/40) or soft tissue (350/50) window.
Dose recommendations: Dmean <30 Gy. Doses above 40 Gy have shown to steeply increase the 
incidence of dry eye while doses above 57–60Gy can cause permanent loss of tearing [9].
The details are given in Figures 1–3.
Figure 1. Optic apparatus.
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3. Salivation related structures
3.1. Parotids
Parotids are contoured based on the guidelines given by Water et al. [10] (Table 1). It is to be 
noted that in 20% of the cases, the parotid gland extends anteriorly over the surface of the 
masseter muscle following the parotid duct and in the anterior direction the deep lobe of the 
parotid gland may extend alongside the medial border of the mandible gland may extend 
Figure 2. Optic chiasm.
Figure 3. Eye balls and associated structures.
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OAR Anatomic boundaries
Cranial Caudal Anterior Posterior Lateral Medial
Parotid gland External auditory 
canal, mastoid 
process
Posterior part of 
submandibular 
space
Masseter muscle, 
posterior mandible, 
medial and lateral 
pterygoid muscle
Anterior belly of 
SCM muscle,
Subcutaneous place, 
platysma muscle
Posterior belly of 
digastric muscle, styloid, 
parapharyngeal space
Submandibular 
gland
Medial pterygoid 
muscle, mylohyoid 
muscle
Subcutaneous fat Mylohyoid muscle, 
lateral surface, 
hyoglossus muscle
Parapharyngeal 
space, SCM
Mandible (medial border), 
platysma, medial surface of 
medial pterygoid
Superior and middle PCM, 
anterior belly of digastric 
muscle, mylohyoid muscle 
(lateral surface), hyoglossus 
muscle
Sublingual 
gland
Mucus membrane 
covering FOM
mylohyoid muscle, 
geniohyoid muscle
Mandible, mylohyoid 
muscle
Hyoglossus muscle Medial surface of 
mandibular bone, 
mylohyoid muscle
Genioglossus muscle
Soft palate Hard palate, 
nasopharynx (air 
space)
BOT, Tonsils, 
oropharynx (air 
space)
HP, BOT/tongue, oral 
cavity (airspace)
Pharynx (mucosal 
surface/airspace), 
superior PCM
Pterygoid process, medial 
pterygoid plate, superior 
PCM, medial pterygoid 
m., PPS, palatine tonsil, 
pharyngeal lumen
Upper lip 
glands
Hard palate, nasal 
spine
lower end of upper 
lip
Orbicularis oris 
muscle, subcutaneous 
tissue/fat
Teeth, maxillary 
bone, HP, tongue
Depressor anguli oris 
muscle, buccinator muscle, 
levator anguli oris muscle/
risorius muscle
Lower lip 
glands
Upper edge of 
lower lip
lower edge of 
teeth sockets/
mandibular body
Orbicularis oris 
muscle, subcutaneous 
tissue/fat
Teeth, mandible, 
tongue/air
Depressor anguli oris 
muscle, buccinator muscle,
Buccal mucosa 
glands
Line between 
maxillary process 
and alveolar 
process of maxilla
Alveolar process of 
mandible
Orbicularis oris 
muscle
Posterior edge of 
mandibular body 
and maxilla
Buccinator muscle, 
subcutaneous fat
Mandible, teeth, tongue
SCM—sternocleidomastoid, PCM—pharyngeal constrictor muscle, BOT—base of tongue, HP—hard palate, FOM—floor of mouth.
Table 1. Salivation related structures.
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alongside the medial border of the mandible. The external carotid artery, the retromandibular 
vein and the extracranial facial nerve are enclosed in the parotid gland.
The external carotid artery (ECA), retromandibular vein and the extra-cranial part of facial 
nerve are enclosed in the gland. If contrast agents are used, the vessels can be clearly demar-
cated and can be avoided from the gland contour. But as contrast administration is not rou-
tinely practiced, and to make the contouring practice uniform, it is recommended to include 
the vessels within the gland contour.
Dose recommendations: severe xerostomia or salivary output <25% of baseline can be avoided if 
at least one parotid is restricted to a mean dose <20 Gy or both parotids restricted to <25 Gy [11].
3.2. Submandibular gland
Situated in the floor of the mouth, it is a predominantly serous gland having a large super-
ficial lobe and a small deep process separated by the fibers of mylohyoid. In most cases the 
gland is hypo dense on CT and can be easily demarcated.
Dose recommendations: if deemed oncologically safe, the mean dose to the submandibular 
gland, restricted to 35Gy may reduce xerostomia symptoms [11].
3.3. Sublingual gland
Sublingual gland is the smallest of the three major salivary glands. It is a predominantly 
mucus gland, situated in the anterior part of oral cavity in the sublingual space.
3.4. Extended oral cavity
The extended oral cavity is contoured partly based on the work by Hoebers et al. [12] exclud-
ing the lips and buccal mucosa [4]. It includes the space posterior to the arch of mandible and 
maxilla. Posteriorly it is limited by the uvula, soft palate and the base of tongue.
3.4.1. Soft palate
Soft palate contains numerous minor salivary glands. It is better seen in the sagittal sections 
by a thin air line separating it from the tongue inferiorly. As the salivary glands are distrib-
uted along the length of the soft palate, the entire soft palate is contoured including the uvula.
Dose recommendations: oral cavity dose should be kept as low as possible. Seeking for V45 < 40% 
and V50 < 20% limits mucositis and improves QoL [12].
3.5. Other minor salivary glands
These glands are distributed along the inner aspects of lips and buccal mucosa between the 
mucous membrane and the muscle layer. Maximum depth from the mucosal surface is about 
4 mm with lower lip glands deeper than the upper ones.
Cancer Survivorship6
3.5.1. Lower lip glands
The upper and posterior limit of the lip is better identified in sagittal sections. The lower limit 
corresponds to the caudal limit of teeth sockets or the cranial mandibular body (in case of 
edentulate mandible) [10].
3.5.2. Upper lip glands
As of the lower lip, the lower and posterior extend is more easily made out in the sagittal 
plane. Cranially it extends till the nasal spine [10].
Dose recommendations: seek for a lip dose less than the oral cavity dose. A mean dose of 30Gy 
and 50 Gy for oral cavity and non-oral cavity cancers respectively would be preferable.
Orbicularis oris muscle can be used to delineate the glands anteriorly.
3.5.3. Glands of buccal mucosa
The glands of buccal mucosa are difficult to distinguish. The cranial, caudal and medial bor-
ders are better visualized in the coronal plane.
The abovementioned have been summarized in Table 1: salivation-related structures.
4. Swallowing related structures
4.1. Pharyngeal constrictor muscles
Pharyngeal wall has two layers of muscle (Table 2). The outer circular layer which are the 
pharyngeal constrictor muscles (PCM) and inner longitudinal muscles which are levators 
(stylopharyngeus and palatopharyngeus). PCM has three parts—superior, middle and infe-
rior constrictor. The caudal ends of the levators blend with the PCM. These muscles are usu-
ally hard to differentiate from PCM and are not contoured differently.
4.1.1. Superior PCM
They originate from sphenoid bone from its pterygoid hamulus and insert to the median 
raphe. Different authors have put forward different levels in regards to its cranial border. 
Generally, cranial border of the superior PCM is taken as the caudal tip of the pterygoid 
plate, i.e., the pterygoid hamulus. The lowest fibers of the superior PCM are separated by the 
muddle PCM by stylopharyngeus and glossopharyngeal nerve. These fibers also overlap onto 
the upper fibers of middle PCM. As these changes are hardly made out in CT, most authors 
define the lowest limit of the muscle as the cranial border of hyoid bone. But this can lead to 
missing of half of middle PCM. Thus, the cranial border can be considered at the lower border 
of second cervical vertebra.
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Organ at risk Anatomic boundaries
Cranial Caudal Anterior Posterior Lateral Medial
Superior PCM Inferior tip of 
pterygoid hamulus
Inferior edge of C2 Pterygoid hamulus, BOT, 
pharyngeal lumen
Prevertebral 
muscles
Medial pterygoid 
muscles
Pharyngeal lumen
Middle PCM Superior edge 
of C3
Inferior edge of hyoid BOT, hyoid Prevertebral 
muscles
Hyoid—greater horn. 
Thyroid cartilage—
superior horn
Pharyngeal lumen
Inferior PCM First slice inferior 
to inferior edge of 
hyoid
Inferior edge of 
arytenoid cartilage
Soft tissue of supraglottis/
glottis
Prevertebral 
muscles
Superior horn of 
thyroid cartilage
Cricopharyngeal 
muscle
First slice inferior 
to arytenoid 
cartilage
Inferior edge of cricoid Posterior edge of cricoid Prevertebral 
muscles
Thyroid gland/
cartilage, fatty tissue
EIM First slice inferior 
to cricoid
1 cm inferior to the 
upper extend
Tracheal lumen Prevertebral 
muscles
Thyroid gland, fatty 
tissue
Cervical 
esophagus
1 cm inferior to the 
cricoid
Sternal notch
BOT Inferior edge of C1 Superior edge of hyoid Posterior 1/3 from 
mandibular bone to 
pharyngeal lumen
Pharyngeal lumen Width of the lumen of 
pharynx
Supraglottic larynx Tip of epiglottis First slice superior to the 
arytenoid cartilage
Hyoid, thyroid cartilage, 
preepiglottic space
Pharyngeal lumen, 
inferior PCM
Thyroid cartilage Pharyngeal lumen 
(lumen to be 
excluded)
Glottic larynx Superior edge of 
arytenoid cartilage
Inferior edge of cricoid 
cartilage (only the soft 
tissue element)
Thyroid cartilage Inferior PCM, 
pharangeal lumen/
cricoid
Thyroid cartilage Pharyngeal lumen 
(lumen to be 
excluded)
Table 2. Swallowing related structures.
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4.1.2. Middle PCM
The fibers originate from the greater and lesser horns of hyoid bone and insert along the 
median raphe. The upper fibers overlap, therefore these boundaries are arbitrary. The upper 
border is taken as the lower border of superior PCM. Lower border corresponds to the lower 
border of hyoid bone.
4.1.3. Inferior PCM
The thickest of the three constrictors, the inferior PCM has two parts—the thyropharengeal 
part which originate from the oblique line of thyroid cartilage and the cricopharyngeal part 
which originate from the lateral part of thyroid cartilage. Most authors delineate these two 
structures separately. The thyropharyngeus is referred to as inferior PCM and the latter is 
referred to as cricopharyngeal muscle. As functionally these muscles are different, they are 
contoured differently.
The inferior PCM is starts cranially from the caudal end of middle PCM, usually one slice 
below the caudal end of hyoid. The caudal border corresponds to the upper border of cricoid, 
just below the level of arytenoid.
Anteriorly, the inferior PCM attaches to the posterior edge of thyroid cartilage, which can be 
recognized easily on CT, while the posterior border is defined by the prevertebral muscles.
Dose recommendations: Dmean < 50 Gy.
4.1.4. Cricopharyngeus
Delineation starts cranially one slice below the level of arytenoids which also corresponds to 
the lower limit of inferior PCM. The contour continues till the lower end of cricoid cartilage.
4.2. Esophageal inlet muscles (EIM)
Levendag et al. [10] recommends contouring the proximal 1 cm of esophagus as a separate 
structure. The cranial border starts from the caudal end of cricopharyngeus.
4.3. Cervical esophagus (CE)
The contouring of CE varies from authors [13, 14]. For the purpose of consistency the upper 
border of CE starts 1 cm below the esophageal inlet muscles and end at the level of sternal 
notch.
4.4. Base of tongue (BOT)
The delineation of BOT has been provided by three authors. All of them are consistent with 
the cranial extend defined as just below the soft palate. As this boundary is difficult to iden-
tify in CT, the lower end of anterior tubercle of C1 vertebra (which corresponds to the same 
level) may be taken for the demarcation. The three authors vary in the definition of the lower 
Overview of Important “Organs at Risk” (OAR) in Modern Radiotherapy for Head and Neck Cancer (HNC)
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extend. The lower limit of hyoid [13], the vallecular and the first slice of epiglottis [14] are 
mentioned, but for consistency, we follow the upper end of body of hyoid as the lower caudal 
limit of BOT.
4.5. Contouring of larynx structures
Freedman et al. [15] has provided a 3 step method to delineate larynx. Step 1 and 3 identifies 
the cranial and caudal limit of larynx. The contouring starts form the slice just below the 
caudal edge of hyoid and ends where the cricoid cartilage is seen as a complete ring. Step 2 
mentions the circumference limits of the larynx. The anterior border corresponds to the inner 
surface of the thyroid cartilage. The posterior border in the upper part corresponds to the 
lateral surfaces of the aryepiglottic folds and the posterior surface of the mucosa covering the 
arytenoids. In the lower part it corresponds to the posterior surface of the cricoid cartilage. 
The pyriform sinus is not to be included in the contour.
The above guidelines contour the larynx as a single structure. As the larynx consists of sub-
glottic, glottic and the supraglottic area, several authors have delineated these sub-sites sepa-
rately. The supraglottis includes the epiglottis, the aryepiglottic folds, the arytenoids, and the 
false vocal cords. The glottis is composed of the true vocal cords and the subglottis extends 
from lower end of glottis to lower edge of cricoid.
The delineation of supraglottis and glottis is based on the function of the two subsites. While 
the supraglottis includes the muscles responsible for the closure of larynx, the glottis part is 
responsible for the movement of the vocal cords.
4.5.1. Supraglottic larynx
The contour includes the supraglottic adductors (oblique arytenoids and aryepiglottic mus-
cles) and epiglottis. The cranial border is the tip of the epiglottis and the contour continues 
inferiorly till the upper edge of arytenoid cartilage.
4.5.2. Glottis
The contour starts from the upper end of arytenoid cartilage and ends caudally at the lower 
edge of the cricoid. Only the soft tissue is contoured (except for the arytenoids). The cricoid 
and the thyroid cartilage should be excluded.
Dose recommendations: To minimize laryngeal edema, the volume of larynx receiving 50 Gy 
and mean dose should be kept as low as possible, ideally ≤20% and 40 Gy respectively [16].
The above has been summarized in Table 2: Swallowing related structures.
5. Brachial plexus
Guidelines for contouring brachial plexus has been put forward by Hall et al. They have 
put forward step-by-step technique. The contour starts form the neural foramina of C5-T1. 
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It extends from outer edge of spinal canal to the space between anterior and middle scalene. 
Where no spinal foramina was present, only the space between anterior and middle scalene is 
contoured. The middle scalene will end in the region of the subclavian neurovascular bundle. 
In the lower part, the brachial plexus is contoured in the posterior aspect of neurovascular 
bundle in the inferior and lateral aspect one to two slices below the clavicle.
Dose recommendations: Dmax <60Gy. Emami et al. [17] has suggested TD 5/5 for the entire 
brachial plexus to be 60Gy. More recent studies with longer follow-up (upto 20 years) have 
shown that the risk of plexopathy keeps rising even after 5 yrs. and may not be apparent until 
20 years after radiation [18].
6. Intra cranial structures
6.1. Ear structures
Ear structures (both the middle ear and inner ear) should be contoured using the bone 
window.
6.1.1. Middle ear
The eustachian tube (ET), tympanic cavity and the mastoid air cells (M) may be contoured 
separately based on the CT/MRI anatomy.
Dose recommendations: ET D30 < 52Gy; M D0.05cc < 41 Gy. Based on the study by Yao et al. [19], dose to 30% of ET and 0.5 cc of mastoid volume were the main predictors of severe ear disor-
ders. Doses above these are associated with increase in grade 2 ear disorders post RT.
6.1.2. Cochlea
It is a small spiral structure of about 0.6cm3 volume located in the petrous part of temporal 
bone. The small bony cavity can be visualized better with a setting of 120/1500 on CT. The 
structures of inner ear are visualized more in T2 weighted MRI images. The semicircular 
canals should not be contoured.
Dose recommendations: Dmean <45 Gy. In children it is advisable to keep it below 35 Gy. [20]
6.1.3. Vestibular and semicircular canal
Arranged in 3 planes, the canals are contoured in bone window (120/1500). They are located 
lateral and superior to the cochlea.
6.2. Brain stem
Brain stem comprises of midbrain, pons and medulla. The cranial extend starts from the level 
of inferior section of lateral ventricle. The organ is better visualized better in MRI. The contour 
extends till the level of the tip of dense of C2 vertebra or foramen magnum.
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6.2.1. Midbrain
It starts from the nigral substance of the cerebral peduncle and ends upper border of pons.
6.2.2. Pons
Better visualized as an oval structure in sagittal sections, it is easily delineated.
6.2.3. Medulla
Medulla starts from the lower end of pons to the lever of tip of dense of axis.
Dose recommendations: Dmax—54 Gy. The entire brain stem can be treated to a dose of 54 Gy 
with little risk of serious side effects. [21]. Mean time of onset of symptom is 17 months (range 
4.5–19 months). Smaller volumes (1-10 cc) may be irradiated to 59Gy at fractionations ≤2Gy [22].
6.3. Pituitary gland
A small gland, it is difficult to visualize in CT, but sella turcica can be used as a surrogate 
marked and the inner boundary of the same can be contoured for its delineation. The gland 
lies immediately below the brain and is connected to the hypothalamus by its stalk.
CT density of pituitary gland is similar to brain. Upon contrast administration, the gland may 
become more hyperintense than brain due to the rich vascular supply.
Dose recommendations: DMax 45Gy (for pan hypopituitarism, lower for Growth hormone (GH) 
deficiency). The anterior pituitary has 5 different types of cells, each with different radiosensi-
tivity. Most sensitive is the GH axis followed by the gonadotropin, ACTH and TSH axis. GH 
deficiency has been noted in relatively lower doses, and has been reported for TBI for doses 
as low as 10 Gy [23], but the incidence increases substantially after 30 Gy where the incidence 
can be as high as 50–100%.
6.4. Temporal lobe
Contouring of temporal lobe should include the hippocampus, parahippocampal gyrus and 
the uncus. The basal ganglia and insula are excluded from the contour. Cranially it starts for 
the superior end of sylvian fissure and ends inferiorly at the base of middle cranial fossa. 
Medial boundary is marked by cavernous sinus, sphenoid sinus and the sylvian fissure and 
laterally by the temporal bone.
7. Discussion
The modern radiotherapy in HNC have revolutionized treatment outcome especially in 
terms of acute and late toxicity. It thus brings about a clear change in treatment outcome. One 
important aspect in preserving the QOL is the OAR’s. We, as radiation oncologist are much 
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aware about the importance of accurate delineation of these structures. Only an accurate 
delineation can lead to effective sparing and thus a desirable outcome in terms of QOL. There 
were several isolated guidelines available. In this chapter we tried to summarize all the avail-
able guidelines. For certain organs like temporal lobe, multiple guidelines are available in 
the literature. We have tried to incorporate them together to put forward a single uniform 
consensus. Having said that the delineation and the attempted dose constraints should also 
be evaluated based on the target volume and tumor control. In case of parallel structures, 
the target volume coverage should be made priority and the risks and side effects of the 
same should be communicated to the patients. In such cases the volume of OARs outside 
the planning target volume (PTV) may be delineated separately and similar dose constrains 
may be aimed for. It should also be kept in mind that even with the most sophisticated of 
technologies, not all of the dose constraints might not be achieved due the basic physics of the 
photon beam. In such situations a trade-off should be agreed upon. However, such liberties, 
should not be attempted with serial structures like spinal cord and brain stem. Organs such 
as these should always be given hard constraints. If the PTV is overlapping such structures, 
under dose the area is accepted.
8. Conclusion
The chapter summarizes basic day to day information for a radiation oncologist to delineate 
OAR’s in HNC radiotherapy. There are several updates and the readers are encouraged to 
go through them at a regular interval. We will be publishing a detail clinical end point based 
acute and late toxicities of these OAR’s at a later date.
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